This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Drug Stocks Unworthy of Biotech Bull Market

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Regeneron Pharmaceuticals (REGN - Get Report)

Stock return since Jan. 1: 84%

I was on the fence about including Regeneron on this list until the stock strolled past $100 per share Monday. I get it -- Regeneron has a newly approved and launched eye drug, Eylea, that's requires fewer inconvenient, uncomfortable (creepy?) eye injections than Roche's Lucentis (and repurposed, off-label Avastin) for treating age-related macular degeneration. But Regeneron is now valued at well over $9 billion. Even if Eylea does really well and brings in $1 billion in sales (not a sure thing by any means), Regeneron's valuation is bubblicious. Regeneron is the new Vertex Pharmaceuticals (VRTX).

Regeneron shares closed Tuesday down less than 1% to $100.34.
3 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
ENMD $1.12 6.67%
CYTX $0.37 0.00%
GALE $1.49 0.00%
REGN $563.10 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs